Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 50,000 shares of the business’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $28.71, for a total value of $1,435,500.00. Following the completion of the sale, the director now owns 1,187,275 shares in the company, valued at $34,086,665.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Gregory Bailey also recently made the following trade(s):

  • On Wednesday, December 20th, Gregory Bailey sold 39,430 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $26.31, for a total value of $1,037,403.30.
  • On Thursday, November 30th, Gregory Bailey sold 9,970 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $25.48, for a total value of $254,035.60.
  • On Friday, November 24th, Gregory Bailey sold 600 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $26.02, for a total value of $15,612.00.
  • On Monday, November 27th, Gregory Bailey sold 20,600 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $25.92, for a total value of $533,952.00.

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) traded up $1.11 on Friday, hitting $29.96. The stock had a trading volume of 576,617 shares, compared to its average volume of 353,050. The company has a market capitalization of $1,080.00 and a PE ratio of -5.74. Biohaven Pharmaceutical Holding Co Ltd has a 1 year low of $17.00 and a 1 year high of $39.51.

Several brokerages have weighed in on BHVN. Zacks Investment Research cut Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. BidaskClub cut Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Thursday, October 5th. Piper Jaffray Companies reissued a “buy” rating and set a $54.00 price objective on shares of Biohaven Pharmaceutical in a research note on Tuesday, September 12th. Canaccord Genuity began coverage on Biohaven Pharmaceutical in a research note on Friday, December 15th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, William Blair reissued an “outperform” rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $36.14.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BHVN. Legal & General Group Plc bought a new position in shares of Biohaven Pharmaceutical during the third quarter valued at approximately $119,000. Nationwide Fund Advisors bought a new position in shares of Biohaven Pharmaceutical during the third quarter valued at approximately $214,000. American International Group Inc. bought a new position in shares of Biohaven Pharmaceutical during the third quarter valued at approximately $251,000. State of Wisconsin Investment Board bought a new position in shares of Biohaven Pharmaceutical during the third quarter valued at approximately $262,000. Finally, Susquehanna International Group LLP bought a new position in shares of Biohaven Pharmaceutical during the third quarter valued at approximately $302,000. 47.76% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Gregory Bailey Sells 50,000 Shares” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/05/biohaven-pharmaceutical-holding-co-ltd-bhvn-director-gregory-bailey-sells-50000-shares.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.